A retrospective study evaluating association between tumour growth rate during previous treatment for tumour response to regorafenib and trifluridine/tipiracil in metastatic colorectal cancer (mCRC)
Latest Information Update: 21 Feb 2018
Price :
$35 *
At a glance
- Drugs Regorafenib (Primary) ; Tipiracil/trifluridine (Primary)
- Indications Colorectal cancer
- Focus Therapeutic Use
- 21 Feb 2018 New trial record
- 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium